Diurnal Group (DNL) Reaches New 12-Month High at $181.30
Shares of Diurnal Group PLC (LON:DNL) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as GBX 181.30 ($2.50) and last traded at GBX 177.50 ($2.45), with a volume of 5000 shares traded. The stock had previously closed at GBX 173.50 ($2.40).
Separately, Numis Securities reissued a “buy” rating and set a GBX 185 ($2.56) price target on shares of Diurnal Group in a research report on Tuesday, February 13th.
The stock has a market cap of $124.56 and a PE ratio of -986.11.
TRADEMARK VIOLATION NOTICE: This article was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2018/02/19/diurnal-group-dnl-reaches-new-12-month-high-at-181-30.html.
Diurnal Group Company Profile
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.